Amicus Therapeutics (NASDAQ:FOLD) issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.09), Morningstar.com reports. The company had revenue of $34.00 million for the quarter, compared to analysts’ expectations of $37.82 million. Amicus Therapeutics had a negative net margin of 386.18% and a negative return on equity of 64.11%. The business’s revenue was up 103.6% on a year-over-year basis. Amicus Therapeutics updated its FY 2019 guidance to EPS.
FOLD stock traded up $0.39 on Friday, reaching $11.35. 249,079 shares of the company traded hands, compared to its average volume of 2,293,359. Amicus Therapeutics has a one year low of $8.27 and a one year high of $17.62. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.45. The firm has a market cap of $2.80 billion, a PE ratio of -8.51 and a beta of 1.79.
In other Amicus Therapeutics news, insider Jay Barth sold 50,000 shares of Amicus Therapeutics stock in a transaction on Friday, April 5th. The stock was sold at an average price of $14.20, for a total value of $710,000.00. Following the completion of the sale, the insider now owns 179,767 shares of the company’s stock, valued at approximately $2,552,691.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO John F. Crowley sold 20,000 shares of Amicus Therapeutics stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $13.51, for a total value of $270,200.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 90,000 shares of company stock valued at $1,252,800. 2.90% of the stock is owned by corporate insiders.
Several equities research analysts recently weighed in on FOLD shares. BidaskClub cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, April 23rd. Cantor Fitzgerald reiterated a “buy” rating and issued a $20.00 price objective on shares of Amicus Therapeutics in a report on Tuesday, February 26th. ValuEngine upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Zacks Investment Research upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, May 3rd. Finally, Robert W. Baird set a $20.00 price objective on Amicus Therapeutics and gave the stock a “buy” rating in a report on Monday, April 22nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $18.19.
WARNING: “Amicus Therapeutics (NASDAQ:FOLD) Announces Earnings Results” was published by Rockland Register and is the sole property of of Rockland Register. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://rocklandregister.com/2019/05/31/amicus-therapeutics-fold-posts-earnings-results-misses-expectations-by-0-26-eps.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Recommended Story: How analysts view the yield curve
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.